- Home
- DXR vs DTIL Comparison
DXR vs DTIL Comparison
Compare DXR & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- DTIL
- Stock Information
- Founded
- DXR 1970
- DTIL 2006
- Country
- DXR United States
- DTIL United States
- Employees
- DXR N/A
- DTIL N/A
- Industry
- DXR Medical/Dental Instruments
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- DTIL Health Care
- Exchange
- DXR Nasdaq
- DTIL Nasdaq
- Market Cap
- DXR 46.9M
- DTIL 55.3M
- IPO Year
- DXR N/A
- DTIL 2019
- Fundamental
- Price
- DXR $13.00
- DTIL $6.64
- Analyst Decision
- DXR Strong Buy
- DTIL Strong Buy
- Analyst Count
- DXR 1
- DTIL 2
- Target Price
- DXR $25.00
- DTIL $47.00
- AVG Volume (30 Days)
- DXR 6.1K
- DTIL 121.7K
- Earning Date
- DXR 01-01-0001
- DTIL 11-03-2025
- Dividend Yield
- DXR N/A
- DTIL N/A
- EPS Growth
- DXR 3.46
- DTIL N/A
- EPS
- DXR 0.36
- DTIL N/A
- Revenue
- DXR $66,306.00
- DTIL $1,261,000.00
- Revenue This Year
- DXR N/A
- DTIL N/A
- Revenue Next Year
- DXR N/A
- DTIL $135.19
- P/E Ratio
- DXR $35.22
- DTIL N/A
- Revenue Growth
- DXR N/A
- DTIL N/A
- 52 Week Low
- DXR $6.55
- DTIL $3.61
- 52 Week High
- DXR $14.00
- DTIL $9.20
- Technical
- Relative Strength Index (RSI)
- DXR 57.62
- DTIL 76.31
- Support Level
- DXR $12.70
- DTIL $5.29
- Resistance Level
- DXR $14.00
- DTIL $5.94
- Average True Range (ATR)
- DXR 0.52
- DTIL 0.32
- MACD
- DXR -0.13
- DTIL 0.11
- Stochastic Oscillator
- DXR 50.00
- DTIL 87.63
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.